The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are: Discontinuation of methotrexate after shingrix immunization increase efficacy of the vaccine in patients with RA ? Researchers will compare humoral and cell-mediated immunity against herpes zoster in RA patients who are vaccinated by shingrix, and compare these immunity between RA patients with MTX discontinuation and MTX continuation groups. Participants will: Vaccinated with shingrix twice. MTX continuation group will keep taking MTX after shingrix vaccination, whereas MTX discontinuation group will stop MTX for 2 weeks after shingrix vaccination. Visit the clinic at baseline (first shingrix vaccination), 2 months later for 2nd shingrix vaccination, then 3 \& 6 months later from baseline to achieve blood sample.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
110
methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination
methotrexate continuation group : keep methotrexate
Konkuk University Medical Center
Seoul, South Korea
RECRUITINGCell-mediated immunity (CD4+ and CD8+ T cell against herpes zoster)
Time frame: baseline (before 1st vaccination), 1 months later from 2nd vaccination, 3 months later from 2nd vaccination
, Humoral immunity (anti-VZV antibody, anti-gE antibody)
Time frame: baseline (before 1st vaccination), 1 months later from 2nd vaccination, 3 months later from 2nd vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.